Neurocrine Biosciences (NASDAQ:NBIX) Director George Morrow Sells 7,500 Shares of Company Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 7,500 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $145.79, for a total value of $1,093,425.00. Following the sale, the director directly owned 10,386 shares in the company, valued at approximately $1,514,174.94. This trade represents a 41.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX traded up $19.50 during midday trading on Tuesday, hitting $164.85. 4,056,875 shares of the company’s stock were exchanged, compared to its average volume of 1,234,742. The stock’s 50 day moving average price is $146.49 and its 200-day moving average price is $147.45. The firm has a market cap of $16.76 billion, a P/E ratio of 24.17, a PEG ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the company posted $2.04 EPS. The business’s revenue for the quarter was up 41.3% compared to the same quarter last year. On average, analysts expect that Neurocrine Biosciences, Inc. will post 7.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NBIX. Canaccord Genuity Group raised their price target on Neurocrine Biosciences from $210.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday. Citigroup upped their price objective on shares of Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Zacks Research downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. UBS Group decreased their target price on shares of Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Finally, Weiss Ratings raised shares of Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $201.55.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. BlackRock Inc. bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth $2,310,886,000. Renaissance Technologies LLC lifted its holdings in shares of Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after buying an additional 180,100 shares during the period. First Trust Advisors LP boosted its stake in Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after buying an additional 472,408 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Neurocrine Biosciences during the second quarter valued at about $117,827,000. Finally, Ieq Capital LLC bought a new position in Neurocrine Biosciences during the second quarter valued at about $107,914,000. 92.59% of the stock is owned by institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Quarterly results topped expectations. Revenue increased 41% year over year to $1.12 billion, and earnings were $3.29 per share. Product sales exceeded $1 billion for the first time, with strong demand across the portfolio. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA guidance was raised. Neurocrine now expects 2026 net sales of $2.9 billion to $2.925 billion, reflecting continued demand for its leading product. The company also cited growth from Crenessity. NBIX Beats on Q3 Earnings & Sales, Raises ’26 Ingrezza Sales View
• Positive Sentiment: Several analysts lifted price targets. Canaccord raised its target to $220 and kept a Buy rating; Piper Sandler raised its target to $215 with an Overweight rating, and RBC raised its target to $190 with an Outperform rating. Canaccord Genuity Group recommendations
• Neutral Sentiment: Neurocrine announced a Phase 2 Alzheimer’s study and plans to present its scientific and neuropsychiatry pipeline at the NEI Fall Congress. These developments may support longer-term pipeline visibility, but no study results were reported. Neurocrine Starts Phase 2 Alzheimer’s Study
• Neutral Sentiment: Morgan Stanley raised its price target to $185 but maintained an Equal Weight rating, signaling a more cautious view than the other target increases. Morgan Stanley recommendations

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.